Silica-bonded S-Sulfonic Acid: A Recyclable Catalyst for the Synthesis of Trisubstituted Imidazoles under Solvent-free Conditions
作者:Khodabakhsh Niknam、Mohammad R. Mohammadizadeh、Salimeh Mirzaee、Dariush Saberi
DOI:10.1002/cjoc.201090129
日期:——
Trisubstituted imidazoles have been synthesized in high yields in the presence of silica‐bonded S‐sulfonic acid as a catalyst. The reaction was carried out at 130°C undersolvent‐freeconditions. The reaction work‐up is simple and the catalyst is easily separated from the products by filtration.
Diphenylimidazole and diphenylthiazole derivatives were synthesized and tested as inhibitors of platelet aggregation in in vitro experiments with the rabbit. Diphenylthiazole derivatives (10) were more potent than diphenylimidazole derivatives (4) in inhibiting arachidonic acid-induced platelet aggregation of rabbit platelet-rich plasma. Two diphenylimidazole and eight diphenylthiazole derivatives were evaluated for ex vivo arachidonic acid and collagen-induced platelet aggregation inhibitory activity using guinea pigs. In these compounds, 4, 5-bis(4-methoxyphenyl)-2-(1, 5-dimethyl-2-pyrrolyl)thiazole (10n) showed strong activity in vitro and ex vivo. The ex vivo activity of 10n was 200 times stronger than that of aspirin. The mechanism of the activity of 10n was the inhibition of cyclo-oxygenase.
New class of imidazoles incorporated with thiophenevinyl conjugation pathway for robust nonlinear optical chromophores
作者:Javier Santos、Eric A Mintz、Oliver Zehnder、Christian Bosshard、Xiu R Bu、Peter Günter
DOI:10.1016/s0040-4039(00)02143-2
日期:2001.1
A new series of thermally stable heterocyclic imidazole-based nonlinear optical chromophores has been developed. These chromophores possess a thiophene based stilbene conjugation pathway with a nitro acceptor group attached to the phenyl end. This feature leads to robust chromophores with high thermal stability and enhanced molecular nonlinearity. (C) 2001 Elsevier Science Ltd. All rights reserved.
Neue Imidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
申请人:SCHERING AKTIENGESELLSCHAFT
公开号:EP0077024B1
公开(公告)日:1987-08-12
REGULATED BIOCIRCUIT SYSTEMS
申请人:Obsidian Therapeutics, Inc.
公开号:US20190192691A1
公开(公告)日:2019-06-27
The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.